Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)

Next Previous
Search
Trial Profile

A Phase 1 Study to Compare Bempegaldesleukin Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) (PIVOT IO 011)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Bempegaldesleukin (Primary) ; Cabozantinib (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms PIVOT IO 011
  • Sponsors Bristol-Myers Squibb; Nektar Therapeutics

    • Most Recent Events

    • 26 Feb 2024 Status changed from active, no longer recruiting to completed.
    • 13 Oct 2023 This trial has been discontinued in Spain.
    • 24 Aug 2022 According to ClinicalTrials.gov record, protocol has been amended as treatment arm decreases from 4 to 2, study design changes from randomized to non-randomized. Phase of the trial changes from I/II to I, time frame of primary endpoint changed from 5 years to 2.5 years, trial focus changes from TU and AR to AR

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top